Kevin Vasquez

ORCID: 0000-0003-0062-9389
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chronic Lymphocytic Leukemia Research
  • Monoclonal and Polyclonal Antibodies Research
  • RNA and protein synthesis mechanisms
  • Advanced Breast Cancer Therapies
  • Advanced Fluorescence Microscopy Techniques
  • Photoacoustic and Ultrasonic Imaging
  • Endometrial and Cervical Cancer Treatments
  • Structural Load-Bearing Analysis
  • Toxin Mechanisms and Immunotoxins
  • Influenza Virus Research Studies
  • Cancer-related Molecular Pathways
  • Structural Engineering and Vibration Analysis
  • Peptidase Inhibition and Analysis
  • Lipid Membrane Structure and Behavior
  • Optical Imaging and Spectroscopy Techniques
  • Uterine Myomas and Treatments
  • RNA modifications and cancer
  • PI3K/AKT/mTOR signaling in cancer
  • Chemical Reactions and Isotopes
  • Structural Health Monitoring Techniques
  • Bacterial Genetics and Biotechnology
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies

Dana-Farber Cancer Institute
2020-2023

The University of Texas at Austin
2015-2019

Fairfield University
2017

University of Minho
2013

Cornell University
2012

9507 Background: First-line treatment with an EGFR tyrosine kinase inhibitor (TKI) is standard of care for patients (pts) EGFR-mutated NSCLC. The TKI osimertinib active against the acquired gefitinib-resistant mutation T790M, as gefitinib osimertinib-resistant C797S. Preclinical evidence suggests dual inhibition + may delay emergence resistance. Methods: This ongoing phase I/II study enrolled pts stage IV (L858R or del19) NSCLC, without prior therapy metastatic disease. Treatment in dose...

10.1200/jco.2020.38.15_suppl.9507 article EN Journal of Clinical Oncology 2020-05-20

We report a method for studying membrane fusion, focusing on influenza virus fusion to lipid bilayers, which provides high temporal resolution through the rapid and coordinated initiation of individual events. Each event proceeds series steps, much like multistep chemical reaction. Fusion is initiated by decrease in pH that accompanies "uncaging" an effector molecule from o-nitrobenzaldehyde, photoisomerizable compound releases proton surrounding solution within microseconds long-wave...

10.1021/ac3006473 article EN Analytical Chemistry 2012-09-14

Recent studies have demonstrated that effective protein production requires coordination of multiple cotranslational cellular processes, which are heavily affected by translation timing. Until recently, engineering has focused on codon optimization to maximize rates, mostly considering the effect tRNA abundance. However, as it relates complex multidomain proteins, been hypothesized strategic translational pauses between domains and distinct individual structural motifs can prevent...

10.1021/acssynbio.5b00193 article EN ACS Synthetic Biology 2015-11-26

An intriguing aspect of protein synthesis is how cotranslational events are managed inside the cell. In this study, we developed an in vivo bimolecular fluorescence complementation assay coupled to SecM stalling (BiFC-SecM) study codon usage influences interactions ribosome-associating factors that occur cotranslationally. We profiled ribosomal associations a number proteins, and observed differential association chaperone proteins TF, DnaK, GroEL, translocation factor Ffh as result...

10.1021/acssynbio.9b00344 article EN ACS Synthetic Biology 2019-11-26

Paradela Bridge is a metallic bridge located along the bank of Tua River in northern Portugal. While not currently service, its structure representative many truss structures built across continent between XIX and XX century. Line belongs to Douro area that UNESCO recently declared as world heritage. This study acquires importance since it might serve an insight for other similar all over country. paper comprises historic investigation archived documents, on-site survey evaluate present...

10.4028/www.scientific.net/kem.569-570.390 article EN Key engineering materials 2013-07-31

Abstract The development of targeted therapies has revolutionized the treatment chronic lymphocytic leukemia (CLL). To date, these are generally given continuously, indefinitely, leading to resistance, which is often on target. Venetoclax first-in-class BCL-2 inhibitor was initially approved for continuous therapy in relapsed high-risk CLL. In that context G101V mutation (mut) identified post-progression samples and shown reduce venetoclax binding BCL-2, limiting its efficacy. mut can be at...

10.1158/1538-7445.am2022-3960 article EN Cancer Research 2022-06-15

Endogenous fluorescence is a powerful technique for probing both structure and function of tissue. We show that enabling wide-field microscopy with chemometrics can significantly enhance the performance tissue diagnosis endogenous fluorescence. The spatial distribution absolute concentration fluorophores uncovered non-negative factorization aided by diversity from microscopic autofluorescence color images. Fluorescence quantification in terms its map avoids issues dependent on specific...

10.1117/12.2255615 article EN Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE 2017-02-17

Abstract Background: Endometrial cancer is the most commonly diagnosed gynecologic in US; incidence rising, and survival rates for this are decreasing. There a paucity of effective treatment recurrent endometrial cancer, especially high grade cancers (HGEC) which include serous, carcinosarcoma, endometrioid, clear cell histologies. Models that mimic clinical molecular characteristics HGEC lacking. To support development next generation therapeutics we report on establishment 3D...

10.1158/1538-7445.am2022-3065 article EN Cancer Research 2022-06-15

Abstract Mechanisms of resistance to venetoclax, a highly selective oral BCL2 inhibitor approved for therapy CLL, remain poorly understood and we sought characterize the clonal evolution in patients developing progressive disease on venetoclax. We performed whole-exome sequencing (WES) 7 relapsed/refractory CLL with progressing observed del17p 43% (3/7), TP53 mutation 86% (6/7) unmutated IGHV 71% (5/7) patients. A median four longitudinal tumor samples were sequenced per patient (total...

10.1158/1538-7445.am2021-1097 article EN Cancer Research 2021-07-01
Coming Soon ...